Global Pharmacogenomics Market

Pharmacogenomics Market Size, Share, Growth Analysis, By Product & Service (Instruments, Reagents & Kits, Software & Services), By Technology (Polymerase Chain Reaction (PCR), DNA Sequencing), By Sample Type, By Application, By Region -Industry Forecast 2026-2033

Report ID: SQMIG35H2362 | Region: Global | Published Date: August, 2025
Pages: 191 |Tables: 120 |Figures: 70

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Global Pharmacogenomics Market size was valued at USD 3.5 Billion in 2024 and is poised to grow from USD 3.87 Billion in 2025 to USD 8.6 Billion by 2033, growing at a CAGR of 10.5% during the forecast period (2026–2033).

    Players in the fiercely competitive industry are concentrating on technology integration and strategic alliances. AI-augmented sequencing systems are being invested in by firms such as Thermo Fisher Scientific and Illumina. Collaborations between genomic labs and pharmaceutical companies have increased; Roche's partnerships with up-and-coming testing companies are one example. To satisfy the increasing demand from customized healthcare providers worldwide, numerous companies are working to obtain regulatory authorization for scaled testing kits and multiplex pharmacogenomic panels 'GeneXus Biotech (South Korea, 2019): A precision medicine company called GeneXus Biotech specializes in quick pharmacogenomic profiling, especially for cancer patients. In 2024, it collaborated with top oncology facilities in Seoul to tailor chemotherapy treatments according to each person's unique genetic makeup. This technology reduces side effects and increases treatment efficacy, especially for Asian populations that are underrepresented in Western genome databases.', 'Genomelink (Japan, 2017): Genomelink is a consumer genomics business that provides DTC insights and genetic trait reports. It started adding pharmacogenomic features to its platform in 2025, including antidepressant sensitivity and drug metabolism. By incorporating these features, Genomelink encourages greater public involvement in pharmacogenomics by providing consumers in Japan and other Asian countries with useful wellness and medication insights.', 'Thermo Fisher Scientific', 'Illumina Inc.', 'Qiagen N.V.', 'F. Hoffmann-La Roche AG', 'Myriad Genetics', 'OneOme LLC', '23andMe Inc.', 'GeneDx', 'Admera Health', 'Genomind', 'Dynamic DNA Laboratories', 'Pathway Genomics', 'GenScript Biotech Corporation'

    Pharmacogenomics is essential in customizing treatments according to a patient's genetic composition as personalized medicine becomes more popular. To increase efficacy and decrease adverse medication reactions, organizations such as the Mayo Clinic extended their pharmacogenomics initiatives. Insurers and healthcare providers are incorporating pharmacogenomic testing into routine clinical practice, and the industry is growing due to the accuracy of medicine selection using genetic data.

    AI-Enhanced Genomic Analysis: Artificial intelligence's use in pharmacogenomics is fundamental in the process of speeding genome sequencing, combining, and predicted drug response in the future. Companies such as Tempus and Deep Genomics adapted AI models with pharmacogenomics workflows to explore new therapeutic biomarkers. By adopting innovative technologies, diagnostic precision is improved, time delays in discovery are mitigated, and real-time, clinical decision support is established making pharmacogenomics testing discovery easier, and cheaper, and make the use of pharmacogenomic tests more realistic in both research and hospital practice settings.

    What Makes North America a Global Hub for Precision Medicine?

    Related Reports

    Metabolomics Market
    Buy Now GET FREE SAMPLE
    Genomics Market
    Buy Now GET FREE SAMPLE
    Drug Discovery Informatics Market
    Buy Now GET FREE SAMPLE
    Pharmerging Market
    Buy Now GET FREE SAMPLE
    Bioinformatics Market
    Buy Now GET FREE SAMPLE
    PharmaCovigilance Market
    Buy Now GET FREE SAMPLE
    Biopharmaceuticals Market
    Buy Now GET FREE SAMPLE
    Protein Sequencing Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Pharmacogenomics Market

    Report ID: SQMIG35H2362

    $5,300
    BUY NOW